Profile Response Detail


Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at :

Molecular Profile STK11 loss
Therapy Avelumab + Talazoparib
Indication/Tumor Type lung non-squamous non-small cell carcinoma
Response Type no benefit


  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")


  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Molecular Profile Indication/Tumor Type Response Type Therapy Name Approval Status Evidence Type Efficacy Evidence References
STK11 loss lung non-squamous non-small cell carcinoma no benefit Avelumab + Talazoparib Phase II Actionable In a Phase II trial (SWOG S1900C, LUNG-MAP sub-study), Talzenna (talazoparib) and Bavencio (avelumab) combination therapy did not meet the efficacy threshold in patients with advanced or recurrent non-squamous non-small cell lung cancer harboring STK11 pathogenic mutations or biallelic loss, resulting in an objective response rate of 2% (1/47) and a disease control rate at 12 weeks of 40% (17/47) (J Clin Oncol 40, no. 16_suppl (June 01, 2022) 9060; NCT04173507). detail...
PubMed Id Reference Title Details
A phase II study of talazoparib plus avelumab in patients with stage IV or recurrent nonsquamous non–small cell lung cancer bearing pathogenic STK11 genomic alterations (SWOG S1900C, LUNG-MAP sub-study, NCT04173507). Full reference...